

Listing of Claims

1-3. (Canceled)

4. (Currently amended) A substantially purified salivary *Lu. longipalpis* polypeptide, wherein the polypeptide comprises ~~an~~the amino acid sequence ~~as~~ set forth as SEQ ID NO: 15, and wherein administration of the polypeptide to a subject produces an immune response to *Lu. longipalpis*.

5-42. (Canceled)

43. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of the polypeptide of claim 4 and a pharmaceutically acceptable carrier.

44. (Currently amended) A method for inducing an immune response to a *Lu. longipalpis* polypeptide in a subject, comprising administering to the subject a therapeutically effective amount of the *Lu. longipalpis* polypeptide of claim 4, ~~or a polynucleotide encoding the *Lu. longipalpis* polypeptide~~, thereby inducing the immune response.

45. (Previously presented) The method of claim 44, wherein the immune response comprises a T cell response.

46. (Previously presented) The method of claim 44, wherein the immune response comprises a B cell response.

47. (Previously presented) The method of claim 44, wherein the subject comprises a non-human veterinary subject.

48. (Previously presented) The method of claim 44, wherein the subject is a dog.

49-51. (Canceled)